SciSparc Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Oz Adler
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Tower A Tel Aviv TA Israel 6971916
- IPO Date
- Aug 30, 2021
- CIK
- 0001611746
- Website
- scisparc.com
- Similar Companies
- Business
- SciSparc Ltd. SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage specialty pharmaceutical company, develops cannabinoid-based therapies targeting central nervous system disorders and rare diseases; its core pipeline includes SCI-110, a proprietary palmitoylethanolamide (PEA) formulation for Tourette syndrome (currently in phase IIb trials), Alzheimer's disease and agitation (phase IIa completed), and related conditions; SCI-210 for autism spectrum disorder (randomized double-blind placebo-controlled trial commenced in early 2024) and status epilepticus; CannAmide, an anti-inflammatory and chronic pain solution; SCI-160 for pain management; SCI-150 for obesity and metabolic disorders; and preclinical candidates for obstructive sleep apnea and chronic pain. The company also operates a nutraceuticals segment through a controlled subsidiary that sells hemp-based products online, including hemp seed oil items such as gummies, oil capsules, gels, creams, detox pills, height pills, antibacterial creams, and anti-aging treatments, primarily via the Amazon.com Marketplace and manufactured in the United States. SciSparc Ltd. maintains strategic manufacturing partnerships, including with Procaps for SCI-110, CannAmide, and PEA oral tablets in softgel form; a collaboration with Clearmind Medicine Inc. since 2021 for combining PEA with 5-MeO-DMT in mental health treatments; and a phase IIa trial agreement with The Israeli Medical Center for Alzheimer's. Founded in 2004 and headquartered in Tel Aviv-Yafo, Israel, the company, formerly Therapix Biosciences Ltd. (name changed January 2021), primarily serves global markets in biotechnology and healthcare with a focus on unmet needs in neurology, psychiatry, and pain management; it listed on Nasdaq in 2017 and employs a lean team of two full-time staff led by CEO and CFO Oz Adler. Recent developments include positive top-line results from the 2024 phase IIa SCI-110 study in Tourette syndrome, demonstrating statistically significant tic severity reduction; a U.S. patent issuance in 2023 (No. 11,547,639) for Tourette treatments using CannAmide combinations; a November 2025 binding term sheet to acquire patents, trademarks, and IP for the MUSE endoscopic system from Xylo Technologies Ltd. (issuing shares for 19.99% ownership) to enter the $3 billion GERD device market via partnerships in North America, Europe, and Latin America; an October 2025 definitive agreement for a controlling interest (63.3 million shares plus contingents) in Miza III Ventures Inc., transferring its pharma portfolio and 51% nutraceuticals stake; and acquisition of 75% (potentially 84%) in Neurothera Labs Inc. along with a new quantum computing initiative for 3D protein modeling in drug discovery.
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
NeuroThera Labs Announces Upsize to Private Placement
NeuroThera Labs Announces C$5,000,000 Private Placement of Units
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
Neurothera Labs Inc. Provides Update On Proposed Acquisition Of Majority Stake In Cliniquantum Ltd.
Neurothera Labs Announces Adoption of Semi-Annual Reporting
Neurothera Labs Announces Continuance into Ontario
Neurothera Labs Engages bullVestor for Investor Relations Activities
Madrigal Pharmaceuticals (NASDAQ:MDGL) versus SciSparc (NASDAQ:SPRC) Financial Review
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease